Cargando…
Ranolazine versus placebo in patients with ischemic cardiomyopathy and persistent chest pain or dyspnea despite optimal medical and revascularization therapy: randomized, double-blind crossover pilot study
BACKGROUND: Patients with ischemic cardiomyopathy (ICM) may continue to experience persistent chest pain and/or dyspnea despite pharmacologic therapy and revascularization. We hypothesized that ranolazine would reduce anginal symptoms or dyspnea in optimally treated ICM patients. METHODS: In this ra...
Autores principales: | Shammas, Nicolas W, Shammas, Gail A, Keyes, Kathleen, Duske, Shawna, Kelly, Ryan, Jerin, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376266/ https://www.ncbi.nlm.nih.gov/pubmed/25848292 http://dx.doi.org/10.2147/TCRM.S82288 |
Ejemplares similares
-
Sex differences in long-term outcomes of coronary patients treated with drug-eluting stents at a tertiary medical center
por: Shammas, Nicolas W, et al.
Publicado: (2014) -
Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
por: Shammas, Nicolas W., et al.
Publicado: (2013) -
Ranolazine for Angina in Hypertrophic Cardiomyopathy
por: Amin, Akhtar, et al.
Publicado: (2018) -
The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization
por: Calcagno, Simone, et al.
Publicado: (2020) -
Ten-year outcome of intraoperative treatment of atrial fibrillation using radiofrequency ablation
por: Boulad, Nour, et al.
Publicado: (2017)